Paula Silverman

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog et al. · Journal of Clinical Oncology · 2017 · 403 citations · Full text

Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer

Matthew J. Ellis, Feng Gao, Farrokh Dehdashti et al. · JAMA · 2009 · 302 citations · Full text

Virtual Reality as a Distraction Intervention for Women Receiving Chemotherapy

Susan Schneider, Maryjo Prince‐Paul, Mary JoAllen et al. · Oncology nursing forum · 2004 · 208 citations

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Crystal S. Denlinger, Tara Sanft, K. Scott Baker et al. · Journal of the National Comprehensive Cancer Network · 2018 · 189 citations · Full text

Palliative Care, Surgical Oncology, Medicine +11